Compumedics (ASX:CMP) Forward Rate of Return (Yacktman) %: 0.00% (As of Jun. 2025)


ASX:CMP Compumedics Ltd ASX:CMP
62 GF Score
Price A$0.23
GF Value A$0.32
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Compumedics Forward Rate of Return (Yacktman) %?

Compumedics ASX:CMP +4.55% 62 Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2025. GuruFocus rates ASX:CMP with a GF Score™ of 62/100 and a GF Value™ of A$0.32 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 377 Medical Devices & Instruments companies, Compumedics ranks worse than 57.03% on this metric.

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Compumedics's forward rate of return for was 0.00%.

The historical rank and industry rank for Compumedics's Forward Rate of Return (Yacktman) % or its related term are showing as below:

ASX:CMP' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.81   Med: 12.51   Max: 20
Current: 5.05

During the past 13 years, Compumedics's highest Forward Rate of Return was 20.00. The lowest was 4.81. And the median was 12.51.

ASX:CMP's Forward Rate of Return (Yacktman) % is ranked worse than
57.03% of 377 companies
in the Medical Devices & Instruments industry
Industry Median: 8.52 vs ASX:CMP: 5.05

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Compumedics  (ASX:CMP) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Compumedics Forward Rate of Return (Yacktman) % Related Terms


Compumedics Forward Rate of Return (Yacktman) % Historical Data

* Premium members only.

The historical data trend for Compumedics's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compumedics Forward Rate of Return (Yacktman) % Chart

Compumedics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Compumedics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:CMP vs ABT, SYK, MDT: Forward Rate of Return (Yacktman) % Comparison

For the Medical Devices subindustry, Compumedics's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compumedics Forward Rate of Return (Yacktman) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Compumedics's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Compumedics's Forward Rate of Return (Yacktman) % falls into.


ASX:CMP
62GF Score
Compumedics Ltd ASX:CMP
Forward Rate of Return (Yacktman) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compumedics Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Compumedics's Forward Rate of Return of Jun. 2025 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0.00083333/0.255+0.0469
=5.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Forward Rate of Return (Yacktman) % of 0.00% mean?
Compumedics (ASX:CMP) has a Forward Rate of Return (Yacktman) % of 0.00% as of Jun. 2025. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Compumedics and its competitors. Over the past decade, Compumedics' Forward Rate of Return (Yacktman) % has ranged from 4.81 to 20.00. According to the industry distribution chart, Compumedics ranks #215 out of 377 companies in the Medical Devices & Instruments industry, placing it in the top 57%.
Is Compumedics' Forward Rate of Return (Yacktman) % too high?
Compumedics' current Forward Rate of Return (Yacktman) % is 0.00%. Over the past 10 years, this metric has ranged from a low of 4.81 to a high of 20.00. Based on the distribution chart, Compumedics ranks #215 out of 377 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Compumedics has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Compumedics' Forward Rate of Return (Yacktman) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Compumedics ranks #215 out of 377 companies for Forward Rate of Return (Yacktman) %. This places Compumedics in the lower half of its industry. The industry median Forward Rate of Return (Yacktman) % is 8.52. Historically, Compumedics' own Forward Rate of Return (Yacktman) % has ranged from 4.81 to 20.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Medical Devices & Instruments company?
The median Forward Rate of Return (Yacktman) % among Medical Devices & Instruments companies is 8.52, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Compumedics and its competitors. For the Medical Devices & Instruments industry, the median Forward Rate of Return (Yacktman) % is 8.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compumedics's current Forward Rate of Return (Yacktman) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compumedics stock overvalued right now?
Based on GuruFocus' analysis, Compumedics (ASX:CMP) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.32, compared to a current price of A$0.23 — trading 28.1% below its estimated fair value. The current Forward Rate of Return (Yacktman) % is 0.00%. Compumedics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Compumedics (ASX:CMP), the current Forward Rate of Return (Yacktman) % is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compumedics (ASX:CMP) Overvalued in 2026?

Based on GuruFocus' analysis, Compumedics stock appears to be undervalued. The current stock price of A$0.23 is trading 28.1% below its estimated GF Value™ of A$0.32. GuruFocus considers Compumedics to be Modestly Undervalued.

Key valuation signals for ASX:CMP:

  • Forward Rate of Return (Yacktman) %: 0.00%
  • GF Value™: A$0.32 vs. price of A$0.23 (28.1% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the ASX:CMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Compumedics Business Description

Address 30-40 Flockhart Street, Abbotsford, Melbourne, VIC, AUS, 3067
Compumedics Ltd is a medical device company. It is engaged in the development, manufacturing, and commercialization of diagnostic technologies for sleep, brain, and ultrasonic blood-flow monitoring applications. The company is organized into geographical operating segments, being the United States of America, Australia and Asia Pacific, and Europe and the Middle East. It derives a majority of its revenue from Australia and the Asia Pacific region.
62GF Score

Get the complete analysis for ASX:CMP

Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.23
Price
A$0.32
GF Value